Taiwan FDA registration 3e96eac96014db9a71b86084f1b9bae9
"Ruimei" triple blood cell separator
TW: "瑞美" 三聯血球細胞分離器
Taiwan·Risk Class 2·REV-MED, Inc.·Registered Apr 20, 2021 – Apr 20, 2026ExpiredRegistration details
- Analysis ID
- 3e96eac96014db9a71b86084f1b9bae9
- Customs Code
- DHA05603439909
Company information
- Manufacturer
- REV-MED, Inc.
- Manufacturer Country
- Korea, Republic of
- Authorized Representative
- BUTICON INTERNATIONAL CORPORATION
Product details
- Intended Use
- The TriCell PRP Kit is designed to remove blood from patients and centrifuge to prepare Platelet-rich plasma (PRP) for patient use.
- Product Type (Level 1)
- B Hematology, pathology, and genetics
- Product Type (Level 2)
- B.9245 Automated hemocytoseparator
- Import Information
- Input;; QMS/QSD
Dates and status
- Registration Date
- Apr 20, 2021
- Expiry Date
- Apr 20, 2026
About this record
Access comprehensive regulatory information for "Ruimei" triple blood cell separator in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 3e96eac96014db9a71b86084f1b9bae9 and manufactured by REV-MED, Inc.. The authorized representative in Taiwan is BUTICON INTERNATIONAL CORPORATION.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices